Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes

The disialoganglioside GD2 is a tumor-associated antigen that may allow for the application of targeted immunotherapies (anti-GD2 antibodies, GD2 CAR T cells) in patients with neuroblastoma and other solid tumors. We retrospectively investigated GD2 expression in a breast cancer cohort, using immuno...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ramona Erber, Sareetha Kailayangiri, Hanna Huebner, Matthias Ruebner, Arndt Hartmann, Lothar Häberle, Julia Meyer, Simon Völkl, Andreas Mackensen, Laura Landgraf, Carol I. Geppert, Rüdiger Schulz-Wendtland, Matthias W. Beckmann, Peter A. Fasching, Nicole Farwick, Claudia Rossig, Paul Gass
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
GD2
breast cancer
immunofluorescence
immunohistochemistry
prognosis
disialoganglioside
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/559414f8e53e4331963a4808b821cd01
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/559414f8e53e4331963a4808b821cd01

Ejemplares similares